US › Healthcare

Immunic Inc (IMUX)

US · Healthcare · Biotechnology

$10.35+2.27%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-34.1M

EPS

$-0.80

EPS estimate

$-1.24

EPS came in at -0.80 against a street estimate of -1.24 — a beat of 35.5%.

Key statistics

Market cap

$155.8M

Forward P/E

0.0

P/B

1.27

Book value

$9.35

EPS (TTM)

$-3.55

52-week high

$17.43

52-week low

$5.06

50-day MA

$14.79

200-day MA

$11.10

Beta

1.41

Analyst view

Analysts rate Immunic Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $43.09.

Shareholding

Insiders

0.97%

Institutions

70.69%

Largest institutional holders

Fund	Stake
Aberdeen Group PLC	6.04%
Bvf Inc	5.61%
Millennium Management LLC	5.43%
Avidity Partners Management LP	4.91%
Jones Hill Capital LP	3.96%
Vanguard Capital Management, LLC	3.77%
LAURION CAPITAL MANAGEMENT LP	2.85%
Morgan Stanley - Brokerage Accounts	2.41%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immunic Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.